← Back to Search

[18F]P17-059 for Parkinson's Disease

Phase 1
Waitlist Available
Led By Martin Pomper, MD PhD
Research Sponsored by Five Eleven Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 - 240 minutes post injection
Awards & highlights

Study Summary

This trial studied the safety of a new imaging agent, [18F]P17-059, in healthy volunteers. The agent was found to be safe and to produce different brain uptake patterns in patients with Parkinson's disease compared to healthy volunteers.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 - 240 minutes post injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 - 240 minutes post injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Therapeutic radiology procedure
Regional brain uptake of [18F]P17-057 in Parkinson patients compared healthy volunteers

Trial Design

3Treatment groups
Experimental Treatment
Group I: Dosimetry in healthy volunteersExperimental Treatment1 Intervention
Group II: Brain uptake and kinetics in healthy volunteersExperimental Treatment1 Intervention
Group III: Brain uptake and kinetics in Parkinson patientsExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[18F]P17-059
2022
Completed Phase 1
~10

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Five Eleven Pharma, Inc.Lead Sponsor
5 Previous Clinical Trials
406 Total Patients Enrolled
Martin Pomper, MD PhDPrincipal InvestigatorJohns Hopkins Medical School

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the option for enrollment still available for this trial?

"Indeed, clinicaltrials.gov displays that this research project is actively trying to recruit patients. This trial was initially posted on 15th July 2022 and has been recently updated on 8th August of the same year. 26 persons are needed for one location only."

Answered by AI

What risks do patients face when administered the drug [18F]P17-059?

"The available data on [18F]P17-059's safety and efficacy is limited, thereby earning a score of 1 in our assessment. As this is the first stage of clinical trials for the drug, caution must be taken when dealing with its administration."

Answered by AI

Could I potentially become a participant in this experiment?

"To qualify for this clinical trial, patients must be diagnosed with parkinson disease and fall within the parameters of 45-90 years old. As such, approximately 26 individuals are being recruited."

Answered by AI

How many participants are joining this experiment?

"Affirmative. According to clinicaltrials.gov, this medical study is actively recruiting patients since its publication on July 15th 2022 and subsequent update 8 days later. The research team seeks 26 participants from one single site for the trial."

Answered by AI

Does this research endeavor include the participation of individuals over 40 years old?

"This trial is seeking patients aged 45 and above, but below the age of 90."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers
2022. "Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03903549.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top